Header Logo

Connection

HASHEM EL-SERAG to Incidence

Back to Details
This is a "connection" page, showing publications HASHEM EL-SERAG has written about Incidence.
HASHEM EL-SERAG
Connection Strength
4.773
Incidence
  1. Race/ethnicity and sex differences in the association between area-level arsenic exposure concentration and hepatocellular carcinoma (HCC) incidence rates in Texas. An ecological study. Environ Res. 2024 Jan 01; 240(Pt 2):117538.
    View in: PubMed
    Score: 0.127
  2. Risk factors for HCC in contemporary cohorts of patients with cirrhosis. Hepatology. 2023 03 01; 77(3):997-1005.
    View in: PubMed
    Score: 0.121
  3. Why Has Screening and Surveillance for Barrett's Esophagus Fallen Short in Stemming the Rising Incidence of Esophageal Adenocarcinoma? Am J Gastroenterol. 2023 04 01; 118(4):590-592.
    View in: PubMed
    Score: 0.119
  4. Recent Decline in the Incidence of Hepatocellular Carcinoma in the United States. Clin Gastroenterol Hepatol. 2023 08; 21(9):2418-2420.e3.
    View in: PubMed
    Score: 0.116
  5. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021 01; 73 Suppl 1:4-13.
    View in: PubMed
    Score: 0.103
  6. Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review. J Gastroenterol Hepatol. 2020 Oct; 35(10):1684-1693.
    View in: PubMed
    Score: 0.100
  7. Texas Has the Highest Hepatocellular Carcinoma Incidence Rates in the USA. Dig Dis Sci. 2021 03; 66(3):912-916.
    View in: PubMed
    Score: 0.099
  8. Risk Factors for Cirrhosis in Contemporary Hepatology Practices-Findings From the Texas Hepatocellular Carcinoma Consortium Cohort. Gastroenterology. 2020 07; 159(1):376-377.
    View in: PubMed
    Score: 0.099
  9. AGA Clinical Practice Update on Screening and Surveillance for Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: Expert Review. Gastroenterology. 2020 05; 158(6):1822-1830.
    View in: PubMed
    Score: 0.098
  10. Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated With Direct Acting Antiviral Agents. Hepatology. 2020 01; 71(1):44-55.
    View in: PubMed
    Score: 0.095
  11. Burden of Gastric Cancer. Clin Gastroenterol Hepatol. 2020 03; 18(3):534-542.
    View in: PubMed
    Score: 0.094
  12. The Epidemiology of Hepatocellular Carcinoma in the USA. Curr Gastroenterol Rep. 2019 Apr 11; 21(4):17.
    View in: PubMed
    Score: 0.092
  13. Risk of Hepatocellular Cancer in Patients With Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2018 12; 155(6):1828-1837.e2.
    View in: PubMed
    Score: 0.088
  14. How we approach it: treatment options for hepatocellular carcinoma. Am J Gastroenterol. 2018 06; 113(6):791-794.
    View in: PubMed
    Score: 0.086
  15. Temporal trend and risk determinants of hepatocellular carcinoma in chronic hepatitis B patients on entecavir or tenofovir. J Viral Hepat. 2018 05; 25(5):543-551.
    View in: PubMed
    Score: 0.086
  16. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017 10; 153(4):996-1005.e1.
    View in: PubMed
    Score: 0.081
  17. The Annual Risk of Esophageal Adenocarcinoma Does Not Decrease Over Time in Patients With Barrett's Esophagus. Am J Gastroenterol. 2017 Jul; 112(7):1049-1055.
    View in: PubMed
    Score: 0.080
  18. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology. 2017 03; 152(4):812-820.e5.
    View in: PubMed
    Score: 0.078
  19. Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection. Hepatology. 2016 07; 64(1):130-7.
    View in: PubMed
    Score: 0.075
  20. Sex and Racial Disparity in Incidence of Esophageal Adenocarcinoma: Observations and Explanations. Clin Gastroenterol Hepatol. 2016 Mar; 14(3):330-2.
    View in: PubMed
    Score: 0.073
  21. Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans. Clin Gastroenterol Hepatol. 2016 Feb; 14(2):301-8.e1-2.
    View in: PubMed
    Score: 0.072
  22. Statin use reduces risk of esophageal adenocarcinoma in US veterans with Barrett's esophagus: a nested case-control study. Gastroenterology. 2015 Nov; 149(6):1392-8.
    View in: PubMed
    Score: 0.071
  23. The incidence of esophageal adenocarcinoma in a national veterans cohort with Barrett's esophagus. Am J Gastroenterol. 2014 Dec; 109(12):1862-8; quiz 1861, 1869.
    View in: PubMed
    Score: 0.068
  24. Racial differences in the progression to cirrhosis and hepatocellular carcinoma in HCV-infected veterans. Am J Gastroenterol. 2014 Sep; 109(9):1427-35.
    View in: PubMed
    Score: 0.067
  25. Risk of upper gastrointestinal cancers in patients with gastroesophageal reflux disease after a negative screening endoscopy. Clin Gastroenterol Hepatol. 2015 Feb; 13(2):280-6.
    View in: PubMed
    Score: 0.066
  26. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology. 2014 Jul; 60(1):98-105.
    View in: PubMed
    Score: 0.066
  27. Statins for chemoprevention of hepatocellular carcinoma: assessing the evidence. Expert Rev Gastroenterol Hepatol. 2013 Aug; 7(6):493-5.
    View in: PubMed
    Score: 0.062
  28. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2014 Jun; 63(6):871-80.
    View in: PubMed
    Score: 0.062
  29. The incidence and prevalence of inflammatory bowel disease among U.S. veterans: a national cohort study. Inflamm Bowel Dis. 2013 Apr; 19(5):1059-64.
    View in: PubMed
    Score: 0.061
  30. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012 May; 142(6):1264-1273.e1.
    View in: PubMed
    Score: 0.057
  31. Risk of colorectal cancer among Caucasian and African American veterans with ulcerative colitis. Inflamm Bowel Dis. 2012 Jun; 18(6):1011-7.
    View in: PubMed
    Score: 0.054
  32. The influence of age, sex, and race on the incidence of esophageal cancer in the United States (1992-2006). Scand J Gastroenterol. 2011 May; 46(5):597-602.
    View in: PubMed
    Score: 0.052
  33. Systematic review: the epidemiology of eosinophilic oesophagitis in adults. Aliment Pharmacol Ther. 2010 Sep; 32(6):712-9.
    View in: PubMed
    Score: 0.051
  34. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010 Jul; 42 Suppl 3:S206-14.
    View in: PubMed
    Score: 0.050
  35. Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma. Minerva Gastroenterol Dietol. 2009 Jun; 55(2):123-38.
    View in: PubMed
    Score: 0.047
  36. Statins and the risk of colorectal carcinoma: a nested case-control study in veterans with diabetes. Am J Gastroenterol. 2009 May; 104(5):1241-8.
    View in: PubMed
    Score: 0.046
  37. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: A population-based study of U.S. veterans. Hepatology. 2009 Jan; 49(1):116-23.
    View in: PubMed
    Score: 0.045
  38. Epidemiology of non-erosive reflux disease. Digestion. 2008; 78 Suppl 1:6-10.
    View in: PubMed
    Score: 0.045
  39. Genetic variants of glutathione S-transferase as possible risk factors for hepatocellular carcinoma: a HuGE systematic review and meta-analysis. Am J Epidemiol. 2008 Feb 15; 167(4):377-89.
    View in: PubMed
    Score: 0.042
  40. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007 Jun; 132(7):2557-76.
    View in: PubMed
    Score: 0.041
  41. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr. 2007 Mar; 150(3):262-7, 267.e1.
    View in: PubMed
    Score: 0.040
  42. The epidemiology of pancreatic cancer in the United States: changes below the surface. Aliment Pharmacol Ther. 2006 Jul 01; 24(1):87-94.
    View in: PubMed
    Score: 0.038
  43. Temporal trends in new and recurrent esophageal strictures in Department of Veterans Affairs. Am J Gastroenterol. 2006 Aug; 101(8):1727-33.
    View in: PubMed
    Score: 0.038
  44. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in the United States. Cancer Epidemiol Biomarkers Prev. 2006 Jun; 15(6):1198-203.
    View in: PubMed
    Score: 0.038
  45. Treatment and outcomes of treating of hepatocellular carcinoma among Medicare recipients in the United States: a population-based study. J Hepatol. 2006 Jan; 44(1):158-66.
    View in: PubMed
    Score: 0.036
  46. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol. 2005 Mar; 42(3):309-14.
    View in: PubMed
    Score: 0.035
  47. Obesity and disease of the esophagus and colon. Gastroenterol Clin North Am. 2005 Mar; 34(1):63-82.
    View in: PubMed
    Score: 0.035
  48. Survival in hepatitis C and HIV co-infection: a cohort study of hospitalized veterans. Clin Gastroenterol Hepatol. 2005 Feb; 3(2):175-83.
    View in: PubMed
    Score: 0.035
  49. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol. 2005 Jan; 100(1):56-63.
    View in: PubMed
    Score: 0.034
  50. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol. 2005 Jan; 100(1):162-8.
    View in: PubMed
    Score: 0.034
  51. Interval Advanced Adenomas and Neoplasia in Patients with Negative Colonoscopy Following Positive Stool-Based Colorectal Cancer Screening Test. Dig Dis Sci. 2025 Jan; 70(1):350-359.
    View in: PubMed
    Score: 0.034
  52. Phase 3 Validation of PAaM for Hepatocellular Carcinoma Risk Stratification in Cirrhosis. Gastroenterology. 2025 Mar; 168(3):556-567.e7.
    View in: PubMed
    Score: 0.034
  53. Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004 Nov; 127(5 Suppl 1):S27-34.
    View in: PubMed
    Score: 0.034
  54. Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology. 2004 Nov; 127(5):1372-80.
    View in: PubMed
    Score: 0.034
  55. Neighborhood-level deprivation mediates racial and ethnic disparities in HCC diagnosis in Texas. Hepatol Commun. 2024 Nov 01; 8(11).
    View in: PubMed
    Score: 0.034
  56. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. Am J Gastroenterol. 2004 Oct; 99(10):1877-83.
    View in: PubMed
    Score: 0.034
  57. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004 May; 24(2):115-25.
    View in: PubMed
    Score: 0.033
  58. Is the length of newly diagnosed Barrett's esophagus decreasing? The experience of a VA Health Care System. Clin Gastroenterol Hepatol. 2004 Apr; 2(4):296-300.
    View in: PubMed
    Score: 0.033
  59. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004 Mar; 39(3):798-803.
    View in: PubMed
    Score: 0.032
  60. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase? J Hepatol. 2004 Mar; 40(3):472-7.
    View in: PubMed
    Score: 0.032
  61. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004 Feb; 126(2):460-8.
    View in: PubMed
    Score: 0.032
  62. Recent Trends in the Incidence of Gastric Cancer in the United States. J Clin Gastroenterol. 2024 01 01; 58(1):39-45.
    View in: PubMed
    Score: 0.032
  63. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med. 2003 Nov 18; 139(10):817-23.
    View in: PubMed
    Score: 0.032
  64. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias? Am J Gastroenterol. 2003 Nov; 98(11):2535-42.
    View in: PubMed
    Score: 0.032
  65. Is there a true "shift" to the right colon in the incidence of colorectal cancer? Am J Gastroenterol. 2003 Jun; 98(6):1400-9.
    View in: PubMed
    Score: 0.031
  66. Geographic variation within the United States in the incidence of hepatocellular carcinoma. J Clin Epidemiol. 2003 May; 56(5):487-93.
    View in: PubMed
    Score: 0.031
  67. Cholangiocarcinoma: the "other" liver cancer on the rise. Am J Gastroenterol. 2002 Dec; 97(12):3199-200.
    View in: PubMed
    Score: 0.030
  68. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol. 2002 Nov-Dec; 35(5 Suppl 2):S72-8.
    View in: PubMed
    Score: 0.030
  69. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002 Nov; 36(5 Suppl 1):S74-83.
    View in: PubMed
    Score: 0.030
  70. Longitudinal Associations of Risk Factors and Hepatocellular Carcinoma in Patients With Cured Hepatitis C Virus Infection. Am J Gastroenterol. 2022 11 01; 117(11):1834-1844.
    View in: PubMed
    Score: 0.029
  71. Neighborhood-Level Factors Contribute to Disparities in Hepatocellular Carcinoma Incidence in Texas. Clin Gastroenterol Hepatol. 2023 05; 21(5):1314-1322.e5.
    View in: PubMed
    Score: 0.029
  72. The epidemic of esophageal adenocarcinoma. Gastroenterol Clin North Am. 2002 Jun; 31(2):421-40, viii.
    View in: PubMed
    Score: 0.029
  73. Epidemiological differences between adenocarcinoma of the oesophagus and adenocarcinoma of the gastric cardia in the USA. Gut. 2002 Mar; 50(3):368-72.
    View in: PubMed
    Score: 0.028
  74. Race/Ethnicity and Birthplace as Risk Factors for Gastric Intestinal Metaplasia in a Multiethnic United States Population. Am J Gastroenterol. 2022 02 01; 117(2):280-287.
    View in: PubMed
    Score: 0.028
  75. A Novel Biomarker Panel for the Early Detection and Risk Assessment of Hepatocellular Carcinoma in Patients with Cirrhosis. Cancer Prev Res (Phila). 2021 06; 14(6):667-674.
    View in: PubMed
    Score: 0.026
  76. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2001 Feb; 5(1):87-107, vi.
    View in: PubMed
    Score: 0.026
  77. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021 04; 18(4):223-238.
    View in: PubMed
    Score: 0.026
  78. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med. 2000 Nov 27; 160(21):3227-30.
    View in: PubMed
    Score: 0.026
  79. Risk of Cirrhosis and Hepatocellular Cancer in Patients With NAFLD and Normal Liver Enzymes. Hepatology. 2020 10; 72(4):1242-1252.
    View in: PubMed
    Score: 0.026
  80. The Incidence and Prevalence of Anxiety, Depression, and Post-traumatic Stress Disorder in a National Cohort of US Veterans With Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020 08 20; 26(9):1423-1428.
    View in: PubMed
    Score: 0.025
  81. Increasing Incidence of Advanced Non-cardia Gastric Cancers Among Younger Hispanics in the USA. Dig Dis Sci. 2021 05; 66(5):1669-1672.
    View in: PubMed
    Score: 0.025
  82. Burden of Pancreatic Cancer: From Epidemiology to Practice. Clin Gastroenterol Hepatol. 2021 05; 19(5):876-884.
    View in: PubMed
    Score: 0.025
  83. Prevalence of Helicobacter pylori Positive Non-cardia Gastric Adenocarcinoma Is Low and Decreasing in a US Population. Dig Dis Sci. 2020 08; 65(8):2403-2411.
    View in: PubMed
    Score: 0.024
  84. Sex and Race Disparities in the Incidence of Hepatocellular Carcinoma in the United States Examined through Age-Period-Cohort Analysis. Cancer Epidemiol Biomarkers Prev. 2020 01; 29(1):88-94.
    View in: PubMed
    Score: 0.024
  85. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999 Mar 11; 340(10):745-50.
    View in: PubMed
    Score: 0.023
  86. Acid suppression medications reduce risk of oesophageal adenocarcinoma in Barrett's oesophagus: a nested case-control study in US male veterans. Aliment Pharmacol Ther. 2018 08; 48(4):469-477.
    View in: PubMed
    Score: 0.022
  87. Factors Associated With Recurrence of Barrett's Esophagus After Radiofrequency Ablation. Clin Gastroenterol Hepatol. 2019 01; 17(1):65-72.e5.
    View in: PubMed
    Score: 0.022
  88. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B. J Hepatol. 2018 08; 69(2):278-285.
    View in: PubMed
    Score: 0.021
  89. Role of Age and Race in the Risk of Hepatocellular Carcinoma in Veterans With Hepatitis B Virus Infection. Clin Gastroenterol Hepatol. 2018 02; 16(2):252-259.
    View in: PubMed
    Score: 0.021
  90. Hepatitis C virus-related complications are increasing in women veterans: A national cohort study. J Viral Hepat. 2017 11; 24(11):955-965.
    View in: PubMed
    Score: 0.021
  91. Risk of oesophageal adenocarcinoma in individuals with Barrett's oesophagus. Eur J Cancer. 2017 04; 75:41-46.
    View in: PubMed
    Score: 0.020
  92. Incidence and Determinants of Hepatocellular Carcinoma in Autoimmune Hepatitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2017 Aug; 15(8):1207-1217.e4.
    View in: PubMed
    Score: 0.020
  93. Esophageal adenocarcinoma after obesity surgery in a population-based cohort study. Surg Obes Relat Dis. 2017 Jan; 13(1):28-34.
    View in: PubMed
    Score: 0.018
  94. Antibiotic Resistance of Helicobacter pylori Among Male United States Veterans. Clin Gastroenterol Hepatol. 2015 Sep; 13(9):1616-24.
    View in: PubMed
    Score: 0.017
  95. Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification. Dig Dis Sci. 2014 Dec; 59(12):3103-10.
    View in: PubMed
    Score: 0.017
  96. The impact of HIV viral control on the incidence of HIV-associated anal cancer. J Acquir Immune Defic Syndr. 2013 Aug 15; 63(5):631-8.
    View in: PubMed
    Score: 0.016
  97. Population-attributable fractions of risk factors for hepatocellular carcinoma in the United States. Am J Gastroenterol. 2013 Aug; 108(8):1314-21.
    View in: PubMed
    Score: 0.015
  98. Incidence and survival of colorectal cancer among Hispanics in the United States: a population-based study. Dig Dis Sci. 2013 Jul; 58(7):2052-60.
    View in: PubMed
    Score: 0.015
  99. Barrett's esophagus in children and adolescents without neurodevelopmental or tracheoesophageal abnormalities: a prospective study. Gastrointest Endosc. 2011 May; 73(5):875-80.
    View in: PubMed
    Score: 0.013
  100. Overview of the viral hepatitis problem. J Fam Pract. 2010 Apr; 59(4 Suppl):S11-6.
    View in: PubMed
    Score: 0.012
  101. The risk of hepatocellular carcinoma in patients with previous malignancy. Cancer Invest. 2008 Jun; 26(5):511-5.
    View in: PubMed
    Score: 0.011
  102. Complications of pediatric colonoscopy: a five-year multicenter experience. Clin Gastroenterol Hepatol. 2008 May; 6(5):515-20.
    View in: PubMed
    Score: 0.011
  103. Incidence of esophageal adenocarcinoma in patients with Barrett's esophagus and high-grade dysplasia: a meta-analysis. Gastrointest Endosc. 2008 Mar; 67(3):394-8.
    View in: PubMed
    Score: 0.010
  104. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007 Oct; 5(10):1221-8.
    View in: PubMed
    Score: 0.010
  105. Complications of pediatric EGD: a 4-year experience in PEDS-CORI. Gastrointest Endosc. 2007 Feb; 65(2):213-21.
    View in: PubMed
    Score: 0.010
  106. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut. 2005 May; 54(5):710-7.
    View in: PubMed
    Score: 0.009
  107. The impact of immigration on the increasing incidence of hepatocellular carcinoma in the United States. Aliment Pharmacol Ther. 2004 Aug 15; 20(4):445-50.
    View in: PubMed
    Score: 0.008
  108. Outcomes of colorectal cancer in the United States: no change in survival (1986-1997). Am J Gastroenterol. 2003 Feb; 98(2):471-7.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.